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Objectives: Rotavirus (RV) is the most frequent cause of severe gastroenteritis fre-
quently requiring hospitalization. RV is responsible for > 1/2 of all hospital stays 
for acute gastroenteritis. The objective was to estimate the burden of community 
acquired rotavirus gastro-enteritis requiring hospitalization (CRVGE) in children ≤ 5 
years old in Czech Republic (CR) and Slovakia (SK). MethOds: Multi-center, retro-
spective patient chart review was conducted in both pediatric and infection disease 
settings in CR (n= 109) and SK (n= 115). Resource use analysis including length of hos-
pital stay and tests performed were evaluated. Patients requiring rehydration, compli-
cations and comorbidities were considered. Direct cost from payer’s perspective were 
retrieved from official DRG lists (CR) and fixed hospitalization cost rates per case (SK). 
Micro-costing was done in parallel based on the resource use data. Results: Mean 
length of hospital stay in CR and SK was 3.9 (SD 1.9) and 4.1 days (SD 1.7) respectively. 
Prevalent diagnostic tests used were latex agglutination 44.0% (CR) and immunochro-
matography 92% (SK). Rehydration was required in 84.4% (CR) and 97% (SK) of cases. 
Comorbidities were reported in 24.8% (CR) and 27% (SK); complications in 10.1% (CR) 
and 7.8% (SK). The national list-based reimbursement per hospitalized CRVGE is € 
370-645 (CR) and € 561 (SK). The calculated average total costs, including treatment 
prior to, and after admission, were € 462 (CR) and € 583 (SK). The major cost item was 
the hospital stay with € 391 (CR) and € 540 (SK). Costs for tests and drugs during hos-
pitalization were € 30 (CR) and € 25 (SK). The costs of pre and post-hospitalization care 
were € 20 (CR) and € 13 (SK). cOnclusiOns: Although the length of hospitalization 
in both countries is similar costs seem to be substantially lower in CR, possibly as a 
result of recently launched DRG system. Common complications and comorbidities 
account for 30% of average hospital costs.
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Objectives: According to WHO the use of antenatal corticosteroids (CEA) in pregnant 
women at risk of preterm birth < 34 weeks can prevent thousands of preterm neonates 
(PN) deaths. The impact of the use of CEA in hospital costs in developing countries is 
not known. Our objective was to compare morbidity and hospital costs of PN whose 
mothers received or not CEA. MethOds: Analysis of PN medical records with gesta-
tional age 26-32 weeks born from Jan/2006-Dez/2009 in a tertiary, public and university 
hospital. We excluded infants with malformations. Maternal characteristics, hospital 
neonatal morbidity, use and doses of CEA and all used resources (tests, medications 
and procedures) were collected. Costs were estimated in Brazilian Reais, from the 
hospital perspective. Results: Of 211 PN, 170 received at least one dose of CEA to 6 
hours before delivery (G1) and 41 did not (G2). The groups had similar characteristics 
but G1 had more male infants (p < 0.05) and cesarean sections (p < 0,00). Morbidity: 
G2 needed more advanced resuscitation (16.5% vs 34%, p = 0.01), experienced more 
intraventricular hemorrhage III / IV (7.6% vs. 22%, p < 0.00) and retinopathy of pre-
maturity (12.4% vs. 24.4%, p = 0.05). Resource use: G1 consumed less mechanical 
ventilation days (5.3 vs 10.6, p = 0.04) and oxygen days (10.7 vs 17, p = 0.02); the num-
ber of NICU and Intermediate Care Nursery days were respectively (19.6 vs 27.5, p = 
0.07) and (24 vs 29.5 days, p = 0.14); there was no difference concerning use of CPAP 
(p = 0.07) and surfactant (p = 0.06). The average cost of hospitalization per patient 
was BRL 18,409 in G1 and BRL 24,090 in G2 (p = 0.03). cOnclusiOns: The CEA is a 
simple measure, which helps to reduce PN morbidity and utilization of health care 
resources, reducing hospital costs.
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Objectives: To examine the burden of illness of patients diagnosed with 
Alzheimer’s disease (AD) in the U.S. veteran population. MethOds: A retrospective 
database analysis was performed using the Veterans Health Administration (VHA) 
Medical SAS datasets from October 1, 2008 through September 30, 2012. Patients 
diagnosed with AD were identified using International Classification of Disease 9th 
Revision Clinical Modification (ICD-9-CM) diagnosis code 331.0. The first diagnosis 
date was designated as the index date. A comparator group was created as well by 
identifying patients without an AD diagnosis but with the same age, region, gender, 
index year, and matching Charlson Comorbidity Index (CCI). The index date for 
the comparator group was randomly chosen to reduce the selection bias. A 1-year 
continuous health plan enrollment was required before and after the index date 
for both groups. One-to-one propensity score matching was used to compare the 
health care costs and utilizations during the follow-up period between the disease 
and comparator groups. Results: A total of 68,856 patients were included in the 
AD and comparison cohorts. After 1:1 matching, a total of 24,542 of patients were 
matched from each group, and the baseline characteristics were proportionate. The 
AD cohort had higher percentages of inpatient (18.46% vs. 2.06%, p< 0.01), emergency 
room (15.80% vs. 4.31%, p< 0.01), physician office (98.17% vs. 58.18%, p< 0.01), outpa-
tient (98.30% vs. 58.92, p< 0.01), and pharmacy visits (84.89% vs. 61.78%, p< 0.01). AD 
patients also incurred higher inpatient ($7,416 vs. $636, p< 0.01), emergency room 
($150 vs. $41, p< 0.01), physician office ($2,752 vs. $1,155, p< 0.01), outpatient visits 
($3,086 vs. $1,300) and pharmacy costs ($774 vs. $350, p< 0.01) compared to patients 
without AD. cOnclusiOns: In this study, AD was associated with higher health 
care resource utilization and a significantly higher economic burden.
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women with EAPP. A recently cost-minimization (CM) model developed for EAPP 
provided the estimates of average treatment cost in Brazil based on local guidelines. 
This CM model compared different treatment pathways for women with EAPP and 
used a 50% improvement in pelvic pain as a definition of a treatment response. A 
patient flow was developed based on epidemiological and demographical data. 
Based on market uptake assumptions, results from the CM model and the patient 
flow, the BIM estimated the incremental budget impact after adopting dienogest. 
The model assumed that during the first year, 6.76% of EAPP patients receive dien-
ogest in detriment of GnRHa. After five years, it was assumed that dienogest would 
capture 30% of the GnRHa market in EAPP. Results: Based on the patient flow 
developed, approximately 0.52% of the population were estimated to be diagnosed 
with EAPP and receiving treatment with GnRHa. In the year after introduction of 
dienogest, the overall budget used to treat EAPP was estimated to decrease by 
up to 2.98% with the budget saving estimated to increase to around 12.98% by 
Year 5. cOnclusiOns: This analysis portends that the budgetary impact of add-
ing dienogest to the public health care system in Brazil, in detriment of the GnRHa, 
result in a budgetary cost saving alternative.
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Objectives: Second-line pharmacological therapy for benign prostatic hyperplasia 
(BPH) includes 5α -reductase inhibitors (5ARIs, dutasteride and finasteride). Aim of this 
study was the evaluation of the budget impact related to the variation in dutasteride 
and finasteride prescribing trends. MethOds: Target population is the number of 
Italian BPH-patients, age ≥ 40 years, treated with dutasteride or finasteride. The BPH-
patients management was modeled on a dynamic cohort for 4-years. Epidemiological 
input data were elaborated from a observational study on pharmaceutical prescrip-
tion data of Italian BPH-patients; hospitalization rates were taken from a cohort study 
investigating BPH-related surgical and not surgical hospitalizations. Costs were cal-
culated as average of Italian DRGs weighted for BPH-related procedure frequency. 
Current Italian prescription shares of dutasteride and finasteride were compared 
with a 20% shift of prescriptions from dutasteride to finasteride (Scenario A) and 
a 20% shift of prescription from finasteride to dutasteride (Scenario B). Results: 
According to current prescribing trends, 372,078 hospitalizations for BPH are expected 
in 4 years. Mean annual cost for BPH-patients management results in 355 million € . 
Hospitalization cost is the main driver (228 milion € /year) while pharmacological ther-
apy accounts for 35% of the total cost (126 million Euro/year). Scenario A: additional 
11.485 hospitalizations related with BPH occur in 4 years; these lead to an increase in 
NHS cost only slightly offset by the savings in drugs acquisition cost: -0,08% savings 
on NHS budget (-0,28 milion € /year) Scenario B: the cost of drugs increases of 5% (+6 
million € /year) and prevents 9,920 hospitalizations in 4 years; the net budget impact 
of scenario B is +0,08% increase in cost (+0,27 milion € /year). cOnclusiOns: The 
shift of prescription from dutasteride to finasteride leads to modest savings on NHS 
Budget while the shift from finasteride to dutasteride offsets the majority of increase 
in drug budget improving the outcome in patients.
PIH12
Costs of AlternAtIVe metHods of CHIld delIVery In serBIA
Odalovic M.1, Lakic D.1, Tadic I.2, Tasic L.2, Petrova G.3
1University of Belgrade Faculty of Pharmacy, Belgrade, Serbia and Montenegro, 2University of 
Belgrade – Faculty of Pharmacy, Belgrade, Serbia and Montenegro, 3Medical University of Sofia, 
Sofia, Bulgaria
Objectives: Different types of labour need different resources. Therefore, 
different costs could be expected. Objectives of this study were to determine if sig-
nificant differences in costs of different type of labour and methods of delivery exist 
and to determine factors related to estimated costs. The costs of spontaneous labour 
with vaginal delivery (SVD), induced labour with vaginal delivery (IVD), and planned 
C-section (CS) without labour were estimated. MethOds: Retrospective, population-
based study was conducted for the period January – December, 2010. Health Insurance 
Fund of Republic of Serbia (HIFRS) database was used as a data source. Direct medical 
costs of mother/newborn pair were estimated. Costs were observed from the perspec-
tive of HIFRS and expressed in European Monetary Unit (EUR). Results: A total of 
99 women were selected for the study sample; average age was 30.55±5.42 years. The 
majority of women (46.5%) had SVD, 28.3% had IVD and 25.2% had CS. Women with 
CS were longer hospitalized compared to women with SVD and IVD (8.52±4.74 vs. 
4.59±2.89 and 5.04±3.01 days, respectively, p< 0.05). Newborns after CS were longer hos-
pitalized compared to newborns after SVD and IVD (5.76±2.20 vs. 4.0±2.07 (p< 0.05) and 
5.14±3.39 (p> 0.05)). Majority of women (88.0%) and children (80.0%) after CS were hos-
pitalized at semi-intensive and/or intensive care unites. The average costs of delivery, 
regardless of the method, were 417.02±284.14 EUR. The costs of C-section were higher 
compare to SVD (640.18±240.04 vs. 243.27±131.70 EUR, p< 0.05) and IVD (640.18±240.04 
vs. 497.10±327.91 EUR, p>0.05). cOnclusiOns: The highest costs of labour in Serbia 
were costs of planned CS. Longer maternal/newborns hospital stay and more 
frequent hospitalization at semi-intensive and/or intensive care unites after CS 
were leading factors of estimated high costs. Considering high costs of CS, it is neces-
sary to review such clinical practice for the purpose of optimizing the use of resources.
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